High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity

Hoskin, Peter; Rojas, Ana M.; Ostler, Peter; Hughes, Robert J.; Alonzi, R.; Lowe, Gerry; Bryant, Linda

doi:10.1016/j.radonc.2013.09.025

Cited by 70 publications

(46 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MOSFET sensitivity factor was determined from the ratio of the MOSFET reading to the expected dose calculated using MC simulation of the water tank setup, using the MC simulation framework described below. Three Gy in 15 fractions of external beam to the prostate and seminal vesicles [16] and 7 patients received a single fraction monotherapy treatment [2]. Plans were prescribed to the prostate D 90 , with 15 Gy and 19 Gy to the 100% isodose levels for boost and monotherapy treatments respectively.…”

Section: Mosfet Calibration and Commissioningmentioning

confidence: 99%

“…Plan objectives were prostate V 100 > 95%, PTV V 100 > 95% (PTV = prostate + 3 mm, 0 mm posteriorly). Constraints were urethra D 10 <17.5 Gy and rectum D2cm 3 < 11.8 Gy, V 100 = 0 for boost [16] and urethra D 10 <22 Gy, D 30 <20.8 Gy, V 150 = 0 and rectum D2cm 3 < 15 Gy, V 100 = 0 for monotherapy [2]. Monte Carlo simulations MC simulations were performed for 10 patient plans to determine the impact of heterogeneities on dose at the MOSFET position.…”

Section: Mosfet Calibration and Commissioningmentioning

confidence: 99%

“…Evidence of the dose-response relationship in prostate cancer [1] has led to increases in the dose per fraction delivered in high dose rate (HDR) prostate brachytherapy with up to 19 Gy prescribed to the 100% isodose in some monotherapy treatments [2]. It is therefore important to have confidence in the dose that is being delivered and there is increasing interest in performing in-vivo dosimetry (IVD) [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Mason¹,

Mamo²,

Al-Qaisieh³

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

Material and methods IVD was performed for 40 treatments planned using intra-operative trans-rectal ultrasound (TRUS) with a MOSFET inserted into an additional needle. Post-treatment TRUS images were acquired for 20 patients to assess needle movement. Monte Carlo simulations of treatment plans were performed for 10 patients to assess impact of heterogeneities.Per-needle and total plan uncertainties were estimated and retrospectively applied to the measured data as error detection thresholds. ResultsThe mean measured dose was -6.4% compared to prediction (range +5.1% to -15.2%). Needle movement and heterogeneities accounted for -1.8% and -1.6% of this difference respectively (mean values for the patients analysed). Total plan uncertainty (k=2) ranged from 11% to 17% and per needle uncertainty (k=2) ranged from 18% to 110% (mean 31%). One out of 40 plans and 5% of needles were outside k=2 error detection threshold. Conclusions

show abstract

Section: Mosfet Calibration and Commissioningmentioning

confidence: 99%

Section: Mosfet Calibration and Commissioningmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Mason¹,

Mamo²,

Al-Qaisieh³

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…HDR plans used the iridium-192 Flexisource (Elekta AB, Stockholm, Sweden) with 2mm dwell spacing. HDR treatments are prescribed to the planned prostate D90 with 19Gy as the 100% isodose and delivered as a single fraction [6]. LDR plans were created in V V M Systems, Inc., Palo Alto, CA) and HDR plans were created in O P 1.3 (Elekta AB).…”

Section: Planningmentioning

confidence: 99%

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer

Murray

Mason

Henry

et al. 2016

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…93,94 HDR was initially used as a boost in conjunction with hypofractionated EBRT for patients with intermediate-to high-risk disease, but, more recently, using this method as a sole treatment has been shown to produce good results. 95,96 The GEC-ESTRO group have recently published an update on the recommendations for the treatment of localized prostate cancer with HDR brachytherapy. 97 The HDR boost technique has been systematically reviewed in a comprehensive article by Zaorsky et al 98 The review shows that the standard EBRT dose varies among centres and is generally delivered as a total dose of 36-54 Gy in 1.8-to 2.0-Gy fractions to the GTV (i.e.…”

Section: Hdr Boost and Monotherapymentioning

confidence: 99%

Recent developments and best practice in brachytherapy treatment planning

Lee

2014

BJR

View full text Add to dashboard Cite

Brachytherapy has evolved over many decades, but more recently, there have been significant changes in the way that brachytherapy is used for different treatment sites. This has been due to the development of new, technologically advanced computer planning systems and treatment delivery techniques. Modern, three-dimensional (3D) imaging modalities have been incorporated into treatment planning methods, allowing full 3D dose distributions to be computed. Treatment techniques involving online planning have emerged, allowing dose distributions to be calculated and updated in real time based on the actual clinical situation. In the case of early stage breast cancer treatment, for example, electronic brachytherapy treatment techniques are being used in which the radiation dose is delivered during the same procedure as the surgery. There have also been significant advances in treatment applicator design, which allow the use of modern 3D imaging techniques for planning, and manufacturers have begun to implement new dose calculation algorithms that will correct for applicator shielding and tissue inhomogeneities. This article aims to review the recent developments and best practice in brachytherapy techniques and treatments. It will look at how imaging developments have been incorporated into current brachytherapy treatment and how these developments have played an integral role in the modern brachytherapy era. The planning requirements for different treatments sites are reviewed as well as the future developments of brachytherapy in radiobiology and treatment planning dose calculation. CHANGES AND DEVELOPMENTS IN TREATMENT PLANNING TECHNIQUESWithin the past few decades, there have been some major changes to the way brachytherapy treatments are both planned and delivered, and the introduction of modern, three dimensional (3D) imaging techniques have contributed significantly. In the 1930s, before the advent of planning computers, treatment planning was carried out by simply following a set of rules according to a dosimetry system such as the Manchester system. [1][2][3] This system was originally developed for use with radium sources and provided information, in tabular form, for the dose specification and distribution of sources and was used for many years. An increase in radiation safety awareness in the 1970s and 1980s led to a decline in the use of radium in favour of the relatively newer and safer radioisotopes such as caesium-137 and iridium-192. Over the same period, technological advances in afterloading techniques and the wider implementation of computerized planning using planar radiographic imaging were being implemented in an attempt to verify the applicator or catheter positions and calculate patient-specific dose. Alongside these advances, the need to compare patients' treatments with those from other treatment centres was being recognized as an important scientific standardization of treatment. The International Commission on Radiation Units and Measurements (ICRU) reports 38 and 58, 4,5 details t...

show abstract

High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity

Cited by 70 publications

References 19 publications

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer

Recent developments and best practice in brachytherapy treatment planning

Contact Info

Product

Resources

About